Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study
Authors
Keywords
-
Journal
CLINICAL RHEUMATOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-30
DOI
10.1007/s10067-021-05609-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis
- (2020) Young Ho Lee et al. ZEITSCHRIFT FUR RHEUMATOLOGIE
- Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study-
- (2020) Kosuke Ebina et al. CLINICAL RHEUMATOLOGY
- Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs
- (2020) Y. H. Lee et al. ZEITSCHRIFT FUR RHEUMATOLOGIE
- Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs
- (2019) Ernest Choy et al. ADVANCES IN THERAPY
- Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study-
- (2019) Kosuke Ebina et al. PLoS One
- What are the dominant cytokines in early rheumatoid arthritis?
- (2018) Laura A. Ridgley et al. CURRENT OPINION IN RHEUMATOLOGY
- Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study-
- (2018) Kosuke Ebina et al. PLoS One
- Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials
- (2018) S.-C. Bae et al. ZEITSCHRIFT FUR RHEUMATOLOGIE
- The emerging safety profile of JAK inhibitors in rheumatic disease
- (2017) Kevin L. Winthrop Nature Reviews Rheumatology
- Low immunogenicity of tocilizumab in patients with rheumatoid arthritis
- (2016) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry
- (2016) Ennio Giulio Favalli et al. ARTHRITIS CARE & RESEARCH
- IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future
- (2015) Go Woon Kim et al. ARCHIVES OF PHARMACAL RESEARCH
- Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis
- (2014) Ryuji Koike et al. Modern Rheumatology
- Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies
- (2014) E. G. Favalli et al. RHEUMATOLOGY
- Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
- (2013) M Neovius et al. ANNALS OF THE RHEUMATIC DISEASES
- Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients
- (2012) Sophie Martin Du Pan et al. ANNALS OF THE RHEUMATIC DISEASES
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
- (2012) Y Kanda BONE MARROW TRANSPLANTATION
- 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
- (2010) D. Aletaha et al. ANNALS OF THE RHEUMATIC DISEASES
- Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008
- (2010) K. L. Hyrich et al. RHEUMATOLOGY
- Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis
- (2009) Sophie Martin Du Pan et al. ARTHRITIS AND RHEUMATISM
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now